1 Min Read
Oct 13 (Reuters) - Merck KGaA
* Says still plan to apply for marketing authorization in Europe, U.S. for avelumab against merkel cell carcinoma this year - CEO in media call Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.